Total Payments
$29,592
2024 Payments
$3,440
Companies
22
Transactions
53
Medicare Patients
4,830
Medicare Billing
$1.2M
Payment Breakdown by Category
Consulting$22,348 (75.5%)
Other$2,725 (9.2%)
Food & Beverage$2,303 (7.8%)
Research$2,008 (6.8%)
Travel$207.80 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $22,348 | 12 | 75.5% |
| Food and Beverage | $2,303 | 36 | 7.8% |
| Unspecified | $2,008 | 2 | 6.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,725 | 1 | 5.8% |
| Honoraria | $1,000 | 1 | 3.4% |
| Travel and Lodging | $207.80 | 1 | 0.7% |
Payments by Type
General
$27,584
51 transactions
Research
$2,008
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CTI BioPharma Corp. | $6,091 | 3 | $0 (2023) |
| SERVIER PHARMACEUTICALS LLC | $5,040 | 4 | $0 (2023) |
| Genentech, Inc. | $5,006 | 4 | $0 (2023) |
| Celgene Corporation | $2,209 | 5 | $0 (2023) |
| F. Hoffmann-La Roche AG | $2,008 | 2 | $0 (2024) |
| MorphoSys, US Inc. | $1,713 | 2 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $1,678 | 10 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,523 | 1 | $0 (2023) |
| GENZYME CORPORATION | $1,513 | 3 | $0 (2022) |
| PharmaEssentia USA Corporation | $1,128 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,440 | 10 | F. Hoffmann-La Roche AG ($2,008) |
| 2023 | $20,913 | 21 | CTI BioPharma Corp. ($6,091) |
| 2022 | $4,979 | 15 | SERVIER PHARMACEUTICALS LLC ($2,730) |
| 2019 | $145.38 | 1 | Stemline Therapeutics Inc. ($145.38) |
| 2017 | $115.28 | 6 | Millennium Pharmaceuticals, Inc. ($29.29) |
All Payment Transactions
53 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | Venclexta (Biological) | — | In-kind items and services | $1,535.45 | Research |
| Study: Best Practices to Overcoming Challenges in Initiating Venetoclax for Patients with Chronic Lymphocytic Leukemia: Results from a United States Community-Based Healthcare Practitioner Survey • Category: BioOncology | ||||||
| 12/31/2024 | F. Hoffmann-La Roche AG | Venclexta (Biological) | — | In-kind items and services | $472.73 | Research |
| Study: Best Practices to Overcoming Challenges in Initiating Venetoclax for Patients with Chronic Lymphocytic Leukemia: Results from a United States Community-Based Healthcare Practitioner Survey • Category: BioOncology | ||||||
| 12/09/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $155.56 | General |
| Category: Oncology | ||||||
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| 09/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $950.00 | General |
| Category: ONCOLOGY | ||||||
| 08/28/2024 | Janssen Scientific Affairs, LLC | TALVEY (Biological) | Consulting Fee | Cash or cash equivalent | $150.00 | General |
| Category: Oncology | ||||||
| 06/02/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $76.05 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 06/02/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $46.49 | General |
| 01/11/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $27.68 | General |
| Category: Oncology | ||||||
| 01/11/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $11.19 | General |
| Category: Oncology | ||||||
| 12/08/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Consulting Fee | Cash or cash equivalent | $2,240.00 | General |
| Category: Oncology | ||||||
| 12/08/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $151.81 | General |
| Category: Hematology | ||||||
| 12/08/2023 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | Cash or cash equivalent | $69.95 | General |
| Category: Oncology | ||||||
| 10/03/2023 | CTI BioPharma Corp. | Vonjo (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,725.00 | General |
| Category: Hematology | ||||||
| 09/30/2023 | Genentech, Inc. | Venclexta (Biological) | Consulting Fee | Cash or cash equivalent | $4,545.00 | General |
| Category: BioOncology | ||||||
| 09/30/2023 | Genentech, Inc. | Venclexta (Biological) | Travel and Lodging | Cash or cash equivalent | $207.80 | General |
| Category: BioOncology | ||||||
| 09/25/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $122.80 | General |
| Category: Hematology | ||||||
| 07/18/2023 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: Oncology | ||||||
| 07/16/2023 | PharmaEssentia USA Corporation | BESREMI (Drug) | Honoraria | Cash or cash equivalent | $1,000.00 | General |
| Category: Oncology | ||||||
| 07/16/2023 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | Cash or cash equivalent | $100.00 | General |
| Category: Oncology | ||||||
| 06/17/2023 | MorphoSys, US Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 06/13/2023 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $1,522.50 | General |
| 05/25/2023 | Janssen Scientific Affairs, LLC | DARZALEX (Biological) | Consulting Fee | Cash or cash equivalent | $1,090.00 | General |
| Category: Oncology | ||||||
| 04/07/2023 | CTI BioPharma Corp. | Vonjo (Drug) | Consulting Fee | Cash or cash equivalent | $4,235.00 | General |
| Category: Hematology | ||||||
| 03/22/2023 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $49.67 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Best Practices to Overcoming Challenges in Initiating Venetoclax for Patients with Chronic Lymphocytic Leukemia: Results from a United States Community-Based Healthcare Practitioner Survey | F. Hoffmann-La Roche AG | $2,008 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 50 | 2,129 | 37,556 | $2.0M | $409,704 |
| 2022 | 55 | 2,097 | 62,836 | $3.5M | $714,704 |
| 2021 | 22 | 604 | 4,791 | $205,217 | $29,838 |
Total Patients
4,830
Total Services
105,183
Medicare Billing
$1.2M
Procedure Codes
127
All Medicare Procedures & Services
127 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 17 | 6,000 | $877,800 | $259,147 | 29.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 113 | 235 | $161,210 | $23,434 | 14.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 86 | 213 | $70,465 | $20,173 | 28.6% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 11 | 6,290 | $132,090 | $14,835 | 11.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 75 | 154 | $35,957 | $9,452 | 26.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 34 | 61 | $28,270 | $8,486 | 30.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 230 | 678 | $42,036 | $6,994 | 16.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 247 | 917 | $32,095 | $6,956 | 21.7% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 25 | 4,680 | $42,120 | $6,426 | 15.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 32 | 106 | $24,910 | $5,777 | 23.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 245 | 607 | $11,533 | $5,076 | 44.0% |
| J9025 | Injection, azacitidine, 1 mg | Office | 2023 | 11 | 13,300 | $199,500 | $4,663 | 2.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $16,983 | $4,219 | 24.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 33 | 33 | $16,797 | $3,609 | 21.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 38 | 64 | $19,456 | $3,077 | 15.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 74 | 263 | $27,615 | $3,060 | 11.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 24 | 48 | $16,032 | $2,395 | 14.9% |
| 83520 | Measurement of substance using immunoassay technique | Office | 2023 | 30 | 130 | $23,530 | $2,200 | 9.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 22 | 36 | $7,812 | $2,161 | 27.7% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 13 | 14 | $7,322 | $1,776 | 24.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 52 | 77 | $11,704 | $1,711 | 14.6% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 16 | 36 | $5,184 | $1,405 | 27.1% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 26 | 59 | $9,204 | $1,270 | 13.8% |
| 96409 | Administration of chemotherapy into vein using push technique | Office | 2023 | 11 | 14 | $6,790 | $1,016 | 15.0% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 41 | 69 | $4,002 | $921.84 | 23.0% |
About Dr. Luke Fletcher, MD
Dr. Luke Fletcher, MD is a Internal Medicine healthcare provider based in Eugene, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/14/2015. The National Provider Identifier (NPI) number assigned to this provider is 1770979098.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Luke Fletcher, MD has received a total of $29,592 in payments from pharmaceutical and medical device companies, with $3,440 received in 2024. These payments were reported across 53 transactions from 22 companies. The most common payment nature is "Consulting Fee" ($22,348).
As a Medicare-enrolled provider, Fletcher has provided services to 4,830 Medicare beneficiaries, totaling 105,183 services with total Medicare billing of $1.2M. Data is available for 3 years (2021–2023), covering 127 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Eugene, OR
- Active Since 04/14/2015
- Last Updated 06/15/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1770979098
Products in Payments
- Venclexta (Biological) $6,761
- Vonjo (Drug) $6,091
- TIBSOVO (Drug) $2,730
- Tibsovo (Drug) $2,310
- ONUREG (Drug) $1,779
- DARZALEX (Biological) $1,194
- BESREMI (Drug) $1,128
- VENCLEXTA (Drug) $950.00
- REBLOZYL (Biological) $407.38
- IMBRUVICA (Drug) $333.37
- Xospata (Drug) $183.25
- TALVEY (Biological) $150.00
- ELZONRIS (Drug) $145.38
- SARCLISA (Biological) $108.58
- Lunsumio (Biological) $103.00
- AYVAKIT (Drug) $101.15
- VONJO (Drug) $76.05
- FOUNDATIONONE (Device) $26.42
- Revlimid (Drug) $23.01
- VORAXAZE (Drug) $18.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Eugene
Miho Dougherty, M.d, M.D
Internal Medicine — Payments: $11,294
Internal Medicine $11,294
Karthik Mahadevan, Md, MD
Internal Medicine — Payments: $6,925
Internal Medicine $6,925
Kirk Jacobson, M.d, M.D
Internal Medicine — Payments: $5,643
Internal Medicine $5,643
Dr. Shehzad Jinnah, Md, MD
Internal Medicine — Payments: $3,561
Internal Medicine $3,561
Dr. Jane Mossberg, M.d, M.D
Internal Medicine — Payments: $2,402
Internal Medicine $2,402
Paul Ehrlich, Do, DO
Internal Medicine — Payments: $1,300
Internal Medicine $1,300